EHDN Platform Meeting: Tuesday, 29 September 2026 Tominersen: GENERATION HD2 Results and Key Learnings Following Roche’s community letter announcing the discontinuation of GENERATION HD2, and EHDN’s Executive Committee statement, we will welcome Peter McColgan, Global Development Leader at Roche, to present the results and key learnings from the Phase 2 clinical trial testing tominersen in Huntington’s disease. 🕓Time: 16:00–17:30 CEST […]
Important Dates
no event
Latest News
Discontinuation of GENERATION HD2 (tominersen) and POINT-HD (RG6496)
On Thursday 9 July 2026, Roche announced the discontinuation of two EHDN-endorsed studies: • GENERATION HD2 (clinicaltrials.gov/study/NCT05686551): A phase 2/open-label extension study of tominersen compared with placebo in Huntington’s disease (HD). • POINT-HD (clinicaltrials.gov/study/NCT07246941): A phase 1 study of RG6496 delivered intrathecally compared with placebo in HD. The community letter from Roche can be read in […]
Professor Jean-Marc Burgunder honoured with European Academy of Neurology Lifetime Fellowship
We are delighted to share that Professor Jean-Marc Burgunder was honoured with a European Academy of Neurology Lifetime Fellowship at its 2026 Congress in Geneva. This recognition is reserved for individuals who have made outstanding, lifelong contributions to neurology in Europe and beyond. A former Chair of EHDN and a valued member of the EHDN […]
FALCON-HD: 12-Month Data – Composite Unified Huntington’s Disease Rating Scale (cUHDRS) Subcomponents
On 30 June 2026, Skyhawk Therapeutics shared further 12-month data from the ongoing phase 1/2 trial of SKY-0515 (also being tested in the EHDN-endorsed phase 2/3 study). Utilising a propensity score-weighted comparison – using Enroll-HD and TRACK-HD natural history datasets – favourable and consistent trends for participants receiving SKY-0515 were found across the four cUHDRS […]
EHDN Newsletter – 58th edition
EHDN News provides regular updates on the network’s activities and highlights key developments relevant to the Huntington’s disease community. The newsletter is published three times a year (March, July and November). We welcome your comments, suggestions and feedback. Please get in touch at newsletter@ehdn.org or contact Catherine Deeprose, Editor. To receive EHDN News directly in your […]
Earthquake Relief Fund
Factor-H is helping HD families affected by the Earthquake in Venezuela. Any donation goes directly the affected families: factor-h.org […]
Earthquake in Venezuela – June 24, 2026
EHDN joins the global Huntington’s disease community in standing with the people of Venezuela in the aftermath of the earthquakes that struck on Wednesday 24 June. Coming amid ongoing geopolitical and economic uncertainty, this is a further blow to an already vulnerable community – including the families of Zulia, whose generations-long participation in HD […]
DEVISE-HD: Developing EVIdence for AntidepreSsant ChoicE to Treat Depression in Huntington’s Disease
Sponsored by Cardiff University (UK), this double-blind randomised controlled trial (RCT) of sertraline, a selective serotonin reuptake inhibitor, will assess the feasibility of conducting a full-scale RCT of the efficacy of antidepressants in HD. Additionally, it will assess some of the current clinical and methodological uncertainties around the effect of antidepressants on HD disease progression. […]
EHDN Elections 2026
Voting is now open! […]
Behavioral Phenotype Working Group: expert opinion survey
Closing date 01 June 2026 […]